Miltefosine (Impavido): the first oral treatment against leishmaniasis

@article{Sindermann2003MiltefosineT,
  title={Miltefosine (Impavido): the first oral treatment against leishmaniasis},
  author={H. Sindermann and S. Croft and K. Engel and W. Bommer and H. Eibl and C. Unger and J. Engel},
  journal={Medical Microbiology and Immunology},
  year={2003},
  volume={193},
  pages={173-180}
}
  • H. Sindermann, S. Croft, +4 authors J. Engel
  • Published 2003
  • Medicine
  • Medical Microbiology and Immunology
  • Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy. 
    Miltefosine and cutaneous leishmaniasis
    18
    In Vitro Activities of Miltefosine and Two Novel Antifungal Biscationic Salts against a Panel of 77 Dermatophytes
    31

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 61 REFERENCES
    Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    51
    Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    133
    Practical Guide for the Treatment of Leishmaniasis
    106
    Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
    427
    Trial of oral miltefosine for visceral leishmaniasis
    215
    Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies.
    45